Drug intelligence / Profile preview

BCM-0241

Development stage: Preclinical
Lead developer: Biocidium Biopharmaceuticals
Modality: Small Molecules
Administration: Oral, Topical

Overview

BCM-0241 is a novel small molecule antibiotic being developed by Biocidium Biopharmaceuticals for the treatment of vancomycin-resistant Enterococci (VRE) infections. It specifically targets vancomycin-resistant *Enterococcus faecalis*. In preclinical studies, BCM-0241 has demonstrated bactericidal activity against VRE. The drug is being developed for both oral and topical administration to address the clinical challenge of multi-drug resistant gram-positive bacterial infections.

Beyond the preview

Go deeper on BCM-0241.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCM-0241.

Explore the full profile